OnKure Therapeutics (OKUR) Competitors $4.78 -0.18 (-3.63%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$4.74 -0.04 (-0.75%) As of 03/25/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock OKUR vs. DMAC, FHTX, DRUG, TSVT, OLMA, NGNE, ATAI, LFCR, ACB, and KRROShould you be buying OnKure Therapeutics stock or one of its competitors? The main competitors of OnKure Therapeutics include DiaMedica Therapeutics (DMAC), Foghorn Therapeutics (FHTX), Bright Minds Biosciences (DRUG), 2seventy bio (TSVT), Olema Pharmaceuticals (OLMA), Neurogene (NGNE), Atai Life Sciences (ATAI), Lifecore Biomedical (LFCR), Aurora Cannabis (ACB), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry. OnKure Therapeutics vs. DiaMedica Therapeutics Foghorn Therapeutics Bright Minds Biosciences 2seventy bio Olema Pharmaceuticals Neurogene Atai Life Sciences Lifecore Biomedical Aurora Cannabis Korro Bio DiaMedica Therapeutics (NASDAQ:DMAC) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, dividends and risk. Which has more volatility and risk, DMAC or OKUR? DiaMedica Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Is DMAC or OKUR more profitable? DiaMedica Therapeutics' return on equity of -43.67% beat OnKure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets DiaMedica TherapeuticsN/A -43.67% -40.81% OnKure Therapeutics N/A -51.17%-47.11% Do institutionals & insiders believe in DMAC or OKUR? 10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 7.2% of DiaMedica Therapeutics shares are held by insiders. Comparatively, 17.9% of OnKure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in DMAC or OKUR? DiaMedica Therapeutics received 87 more outperform votes than OnKure Therapeutics when rated by MarketBeat users. However, 100.00% of users gave OnKure Therapeutics an outperform vote while only 63.09% of users gave DiaMedica Therapeutics an outperform vote. CompanyUnderperformOutperformDiaMedica TherapeuticsOutperform Votes9463.09% Underperform Votes5536.91% OnKure TherapeuticsOutperform Votes7100.00% Underperform VotesNo Votes Which has higher earnings and valuation, DMAC or OKUR? DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDiaMedica TherapeuticsN/AN/A-$19.38M-$0.60-7.62OnKure TherapeuticsN/AN/A-$77.39M-$6.57-0.73 Does the media favor DMAC or OKUR? In the previous week, DiaMedica Therapeutics had 2 more articles in the media than OnKure Therapeutics. MarketBeat recorded 11 mentions for DiaMedica Therapeutics and 9 mentions for OnKure Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.46 beat OnKure Therapeutics' score of -0.05 indicating that DiaMedica Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral OnKure Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend DMAC or OKUR? DiaMedica Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 75.05%. OnKure Therapeutics has a consensus price target of $32.33, suggesting a potential upside of 576.43%. Given OnKure Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe OnKure Therapeutics is more favorable than DiaMedica Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00OnKure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 SummaryDiaMedica Therapeutics beats OnKure Therapeutics on 8 of the 15 factors compared between the two stocks. Remove Ads Get OnKure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKUR vs. The Competition Export to ExcelMetricOnKure TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.22M$6.99B$5.68B$8.30BDividend YieldN/A2.72%4.55%4.02%P/E Ratio-0.397.2324.5519.25Price / SalesN/A230.77395.7294.10Price / CashN/A65.6738.1634.64Price / Book0.186.617.064.46Net Income-$77.39M$142.13M$3.19B$247.07M7 Day Performance-4.40%1.72%0.18%1.77%1 Month Performance-2.85%2.31%5.54%-3.31%1 Year PerformanceN/A-5.07%14.22%5.26% OnKure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKUROnKure Therapeutics2.8718 of 5 stars$4.78-3.6%$32.33+576.4%N/A$64.22MN/A-0.39N/AUpcoming EarningsGap UpDMACDiaMedica Therapeutics1.6237 of 5 stars$5.99+3.8%$7.00+16.9%+70.5%$256.14MN/A-10.7020FHTXFoghorn Therapeutics2.659 of 5 stars$4.60+3.8%$13.17+186.2%-33.2%$255.82M$22.60M-2.40120Positive NewsDRUGBright Minds Biosciences2.9626 of 5 stars$36.27+1.4%$84.33+132.5%+2,874.4%$255.49MN/A-213.34N/ATSVT2seventy bio2.9565 of 5 stars$4.95flat$6.67+34.7%+1.0%$255.36M$45.62M-2.66440Earnings ReportAnalyst ForecastHigh Trading VolumeOLMAOlema Pharmaceuticals2.7992 of 5 stars$4.45+0.9%$28.75+546.1%-61.8%$254.98MN/A-2.0370Earnings ReportNGNENeurogene2.2937 of 5 stars$16.87+1.0%$60.83+260.6%-71.0%$250.60M$925,000.000.0090Earnings ReportAnalyst ForecastNews CoverageATAIAtai Life Sciences2.696 of 5 stars$1.46-1.4%$9.00+516.4%-5.4%$244.99M$331,000.00-1.8080Upcoming EarningsAnalyst RevisionGap UpLFCRLifecore Biomedical1.7816 of 5 stars$6.55+1.2%$8.00+22.1%+20.6%$242.51M$130.86M-11.70690ACBAurora Cannabis0.8441 of 5 stars$4.39-0.5%N/A+9.2%$240.83M$320.81M87.821,073KRROKorro Bio1.504 of 5 stars$25.06+1.7%$144.00+474.6%-72.2%$234.76MN/A0.0070Earnings ReportAnalyst Revision Remove Ads Related Companies and Tools Related Companies DiaMedica Therapeutics Alternatives Foghorn Therapeutics Alternatives Bright Minds Biosciences Alternatives 2seventy bio Alternatives Olema Pharmaceuticals Alternatives Neurogene Alternatives Atai Life Sciences Alternatives Lifecore Biomedical Alternatives Aurora Cannabis Alternatives Korro Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OKUR) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OnKure Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share OnKure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OKUR Stock Free OKUR Stock Alerts